Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

EMA Starts New Review of Heart Risks of Non-Selective NSAIDs

Don't Miss Out —
Follow us on:

Oct. 21 (Bloomberg) -- The European Medicines Agency said it will start a new review of evidence to determine the heart risks associated with painkilling medicines known as non-selective non-steroidal anti-inflammatory drugs.

The drugs, known as NSAIDs, have been the subject of several European reviews relating to gastrointestinal and cardiovascular safety, the agency said today in a statement on its website. The agency plans to update its 2006 opinion that overall the benefits of NSAIDs outweighed the risks, though the possibility of a small increased chance of heart attacks or strokes couldn’t be ruled out.

To contact the editor responsible for this story: Kristen Hallam at khallam@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.